Zdrowie i gospodarka · 04/12/2018

FDA Releases Final Guidance on Post-Complete Response Letter Meetings for Generic Drug Applicants

The FDA has announced the availability of a final guidance document that clarifies the criteria for requesting post-complete response letter meetings with the agency and outlines procedures for managing these meetings, in accordance with the Generic Drug User Fee Amendments (GDUFA II) reauthorization.